Join the BioNap Email List!

BioNap Client List

BioNap is party to a services agreement with companies or afflicates of companies (i.e. IR/PR firms) that are covered on this blog, pursuant to which BioNap is paid in exchange for the provision of research reports, investor relations consulting services, and general consulting services. 

Past and/or current BioNap, Inc. clients include:

- RedHill Biopharma Ltd. (RDHL) at a rate of $2,500 to $5,000 per month to BioNap for the provision of research reports and investor relations services.

- CanFite Biopharma (CANF) at a rate of $4,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- Immune Pharmaceuticals (IMNP) at a rate of $3,500 per month to BioNap for the provision of research reports and investor relations services.

Actinium Pharmaceuticals (ATNM) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

22nd Century Group Inc. (XXII) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

MabVax Therapeutics (MBVX) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

- Relmada Therapeutics (RLMD) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

- BioSig Technologies Inc. (BSGM) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

- Revive Therapeutics (RVV.V) at a rate of $3,333 per month to BioNap for the provision of research reports and investor relations services.

- HedgePath Pharma, at a rate of $2,500 to $4,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- Matinas Biopharma, at a rate of $4,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- BriaCell Therapeutics (BCT.V) at a rate of $2,000 per month to BioNap and has granted Jason Napodano, founder and chief officer of BioNap, 500,000 stock options for the provision of research reports and investor relations services.

- InVivo Therapeutics (NVIV) at a rate of $2,500 for conducting a CEO Interview.

- Exactus Inc (EXDI) has granted Jason Napodano, founder and chief officer of BioNap, 150,000 shares of restricted Series-B1 stock for the provision of research reports and investor relations services.

- BrianStorm Cell Therapeutics (BCLI) at a rate of $3,500 per month to BioNap for the provision of research reports and investor relations services.


- Vaxil Bio Ltd (VXL.V) at a rate of $2,000 per month to BioNap and has granted Jason Napodano, founder and chief officer of BioNap, 75,000 stock options for the provision of research reports and investor relations services.

- VistaGen Therapeutics (VTGN) at a rate of $3,500 per month to BioNap for the provision of research reports and investor relations services.

- Oryzon Genomics (ORY) at a rate of $1,500 to $5,000 per report to BioNap for the provision of research reports and investor relations services.


- Vitality Biopharma Inc. (VBIO) at a rate of $4,000 per month to BioNap for the provision of research reports.

- Pieris Pharmaceuticals (PIRS) at a rate of $5,000 to BioNap for the provision of a research reports and investor relations services.

- CoLucid Pharmaceuticals, Inc. (CLCD) at a rate of $2,500 to $3,500 per report to BioNap for the provision of research reports and investor relations services.


BioNap has also provided exclusive market research, investor relations consulting services, and due diligence on business development activities to several companies, both public and private, none of which has been shared publicly. BioNap expects to continue to provide strategic consulting services to companies, both public and private, in the future that may or may not result in confidential material to be used by the company, not shared on the blog. BioNap reserves the right to hold these projects, including fees earned for providing general consulting services and project work, as confidential material.

No comments:

Post a Comment